← Back to Search

Deprescribing Program for Dementia and Diabetes

N/A
Waitlist Available
Led By Medha Munshi, MD
Research Sponsored by Joslin Diabetes Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will check if a program can reduce the use of medications that cause low blood sugar in people with Alzheimer's and related diseases in long-term care facilities.

Who is the study for?
This trial is for clinical staff at long-term care facilities, including doctors, physician assistants, nurse practitioners, and clinical pharmacists. They must have participated in the STRIDE program aimed at educating on deprescribing diabetes medication for residents with Alzheimer's.Check my eligibility
What is being tested?
The STRIDE educational program is being tested to see if it helps reduce the use of diabetes medications that carry a high risk of causing low blood sugar in elderly patients with dementia. The study will also evaluate how well the program is accepted and implemented by healthcare providers.See study design
What are the potential side effects?
Since this trial focuses on an educational program rather than a medical intervention, there are no direct side effects from drugs or treatments. However, changes in prescribing practices could potentially affect patient health outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use
Secondary outcome measures
Acceptability of the STRIDE Educational Program
Appropriateness of the STRIDE Educational Program
Feasibility of the STRIDE Educational Program

Trial Design

1Treatment groups
Experimental Treatment
Group I: STRIDE InterventionExperimental Treatment1 Intervention
Educational intervention for clinicians
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STRIDE
2019
N/A
~14200

Find a Location

Who is running the clinical trial?

Brown UniversityOTHER
456 Previous Clinical Trials
563,061 Total Patients Enrolled
19 Trials studying Dementia
208,299 Patients Enrolled for Dementia
Joslin Diabetes CenterLead Sponsor
96 Previous Clinical Trials
26,553 Total Patients Enrolled
Theoria MedicalUNKNOWN
1 Previous Clinical Trials
300 Total Patients Enrolled

Media Library

STRIDE Clinical Trial Eligibility Overview. Trial Name: NCT05535478 — N/A
Dementia Research Study Groups: STRIDE Intervention
Dementia Clinical Trial 2023: STRIDE Highlights & Side Effects. Trial Name: NCT05535478 — N/A
STRIDE 2023 Treatment Timeline for Medical Study. Trial Name: NCT05535478 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research initiative actively seeking participants?

"The clinicaltrials.gov website reveals that this research has not been actively recruiting since February 22nd 2023, when the listing was most recently updated. However, there are 1741 other trials which may be suitable for participation currently accepting patients."

Answered by AI
~2 spots leftby Jun 2024